2seventy bio, Inc. (TSVT)

Market Cap	266.15M
Revenue (ttm)	48.37M -32.1%
Net Income	-4.09M
EPS	-0.08
Shares Out	53.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	5.00
Day's Range	n/a
52-Week Range	2.29 - 5.30
Beta	1.05
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2025

About TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: TSVT
• Website: https://www.2seventybio.com

Financial Performance

In 2024, 2seventy bio's revenue was $37.86 million, a decrease of -62.28% compared to the previous year's $100.39 million. Losses were -$57.25 million, -73.69% less than in 2023.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error